Two 6‐year‐old ring‐tailed lemurs (Lemur catta), housed in two different zoological institutions, were evaluated for nonpruritic nodules located on the eyelids, lips and chest. The first lemur was anaesthetized for diagnostic investigations. Although pan‐herpes polymerase chain reaction was positive and bacterial culture yielded Staphylococcus warneri, histopathology of skin biopsies revealed a severe chronic dermatitis and folliculitis with intralesional arthropods, identified as Psorobia sp. on skin scrapings. The second lemur was also diagnosed a psorergatic mange. After several treatment failures, weekly topical applications of amitraz were performed and a minimum of five applications were necessary to notice the complete resolution of the lesions. Amitraz toxicity was not observed, despite the first lemur being pregnant at the time of treatment. This is the first report of psorergatic mange in a prosimian species and the first reported use of amitraz as a successful treatment for this disease.

A 14‐month‐old, female Javan silvered leaf monkey (Trachypithecus auratus auratus) was presented for inguinal circular, erythematous, crusty dermatitis. The animal was bright and alert, and appetite was good. Lesions progressed to the whole abdomen and became ulcerative. Skin biopsies revealed a cutaneous lymphoma and no metastases were detected on computed tomography scan. Anti‐tumoral treatment was attempted with masitinib (50 mg orally every 48 hours), a tyrosine kinase inhibitor. In the absence of improvement of the lesions, as treatment was well tolerated, masitinib dose was increased to 50 mg orally once a day. Effect on the lesions was minimal, clinical condition worsened and the animal died 9 months after initial presentation. Postmortem examination and histopathology confirmed multicentric epitheliotropic CD3+ cutaneous lymphoma. To the authors’ knowledge, this is the first report of cutaneous lymphoma in a langur, and the first attempt of treatment with masitinib in a non‐human primate species. Despite poor response, masitinib treatment appeared safe.